Adverse event reporting patterns of concomitant botanical dietary supplements with CYP3A4 interactive & CYP3A4 non-interactive anticancer drugs in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Shahariar Mohammed FahimAhmed Ullah MishukNing ChengRichard HansenAngela I CalderónJingjing QianPublished in: Expert opinion on drug safety (2018)
This study identified potential protective and risk signals for AEs with concomitant use of BDS and anticancer drugs.